Home 2024

Archives

Still image of highly dynamic chromatin (red) interacts with Arc pucta (green). Shown is a small detail of a neuronal nucleus imaged by high-resolution microscopy. Notice how finger-like extensions of the chromatin transiently visit Arc pucta. The movie is sped up 10 times.

Arc: A new target for treating alzheimer’s disease

Antonius M. VanDongen, Associate Professor from Duke University, walks us through Arc, a new target for treating Alzheimer’s disease.
Digitally generated image, perfectly usable for all kinds of topics related to digital innovations, AI, data processing, network security or technology and computer science in general.

Flame system: Computerised cognitive assessment for remote brain health monitoring

Monitoring brain health, particularly cognition, in older adults is increasingly recognised as a significant priority for research, healthcare and broader public health. Find out here about the development and validation of the FLAME System, a computerised cognitive assessment for remote brain health monitoring.
Neural cells network on a dark background - 3d rendered image of the neural cell network image on a black background. Glowing synapse. Displaying neurons and the neural network. Electrical impulses in neural networks.

Exploring HER-096: A novel approach to Parkinson’s Disease

Parkinson’s disease, a progressive neurodegenerative disorder, poses significant challenges for both patients and researchers. In a recent interview with Henri Huttunen from Herantis Pharma Plc, we delved into the intricacies of their potential novel disease-modifying therapy, HER-096.
Scientific analysis of Alzheimer's disease in hospital, conceptual image

Lecanemab and other treatments: Glimmers of hope for alzheimer’s patients

Effective treatments for amyloid-associated neurological diseases are desperately needed; H. Robert Guy, CEO of Amyloid Research Consultants, talks us through the obstacles and opportunities associated with structure-based drug design.
Brain activity,Human brain damage,Neural network,Artificial intelligence and idea concept

Progress in development of disease-modifying treatments in Parkinson’s Disease

Henri Huttunen, Chief Scientific Officer, Herantis Pharma Plc, charts progress in the development of disease-modifying treatments for Parkinson’s disease.
Neuron cell close-up view - 3d rendered image of Neuron cell on black background. SEM view interconnected neurons synapses. Abstract structure conceptual medical image. Synapse. Healthcare concept, representing Alzheimer's Disease therapeutics

Beyond amyloid: What’s next for Alzheimers disease therapeutics?

Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.
MRI scan of brain

Understanding amyloid beta and Alzheimer’s disease: the key to helping AD patients

Efforts to prevent or treat Alzheimer’s Disease (AD) by targeting Amyloid beta (Aβ) assemblies should be continued, but the strategies should be altered dramatically.
image showing tanycytes in purple and the neurons they interact with in the hypothalamus (yellow: appetite promoting neurons expressing neuropeptide Y (NPY); blue: appetite suppressing neurons expressing the propopiomelanocortin (POMC))

The WATCH project: Tanycytes in health and disease

The WATCH project aims to elucidate how tanycytes mediate physiological processes by acting as gatekeepers between the brain and body, how their dysfunction is involved in various disorders and age-related impairments, and what can be done to prevent or correct these.
old Chinese couple using computer sat at dining table with mugs

Who benefits more from the cognitive effects of B vitamins?

Further understanding of the characteristics of the responders may shed light on how B vitamins benefit brain health and the formulation of more effective forms of B vitamins.
memory decline

Alzheimer’s drug slows memory decline in phase 3 trial

Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.

Follow Us

Advertisements